The APOE gene provides instructions for making a protein called apolipoprotein E, which acts as a transport vehicle for cholesterol and other fats throughout your body and brain. It’s one of the most studied genes in medicine because the version you inherit directly influences your risk for Alzheimer’s disease, cardiovascular problems, and even how long you live. Everyone carries two copies of the gene (one from each parent), and those copies come in three common variants that have meaningfully different effects on health.
What the APOE Protein Does
The protein produced by the APOE gene works like a delivery truck for fats. It attaches to cholesterol and other lipids floating in your blood and spinal fluid, then docks with receptors on cell surfaces to drop off its cargo. This process is how your body distributes and recycles fats between organs, tissues, and individual cells. Without it, lipids would accumulate in the wrong places instead of going where they’re needed.
In the brain, APOE is especially important. It’s produced in abundance there and serves as the primary lipid transport system in cerebrospinal fluid. Brain cells need a constant supply of cholesterol and other fats to maintain their membranes, repair damage, and support the connections between neurons. The APOE protein handles nearly all of that shuttling work. It also plays a role in clearing waste products from the brain, which is where the different gene variants start to matter.
The Three Common Variants
The APOE gene comes in three versions, called alleles: e2, e3, and e4. They differ by just one or two amino acids in the protein they produce, but those small structural changes alter how effectively the protein does its job.
- APOE e3 is the most common variant worldwide, found in the vast majority of people across all populations. It’s considered the baseline: neither protective nor harmful for most health outcomes.
- APOE e4 is carried by roughly 15% to 25% of people. It’s associated with higher LDL cholesterol and increased risk for Alzheimer’s disease. About 2% to 5% of people carry two copies.
- APOE e2 is the rarest of the three, carried by only 5% to 10% of people. It appears to be protective against Alzheimer’s and is linked to longer lifespan.
Since you have two copies of the gene, your genotype is some combination of these: e3/e3, e3/e4, e2/e3, e4/e4, and so on. The specific pairing matters because having one versus two copies of a variant changes the magnitude of its effects.
Geographic Distribution
The frequency of these variants differs significantly across populations. The e3 allele dominates everywhere but ranges from about 97% in some Indian populations to 36% in Papuans. The highest e4 frequencies appear in Central African populations (around 40% in Pygmies and Tutsi) and in Oceania, while Mediterranean and many Asian populations have e4 frequencies below 10%. The e2 allele is rare or absent in Inuit, South American, Siberian, and Mongolian populations but relatively common in sub-Saharan African and Malaysian groups.
APOE and Alzheimer’s Risk
The connection between APOE e4 and Alzheimer’s disease is one of the strongest genetic risk factors known for any common illness. For people of European descent, carrying a single copy of e4 roughly doubles or triples the risk of developing Alzheimer’s compared to someone with two copies of e3. Carrying two copies of e4 increases that risk approximately tenfold. The effect also varies by ethnicity: Japanese individuals with one copy of e4 face about five times the risk, while people of African ancestry with two copies see a smaller increase than Europeans do.
The mechanism comes down to waste clearance in the brain. A sticky protein fragment called amyloid-beta naturally accumulates as a byproduct of brain activity, and the APOE protein helps clear it away. The e3 version of the protein handles this efficiently, activating immune cells in the brain to break down and remove amyloid. The e4 version is measurably worse at this job. It’s slower at stimulating the brain’s cleanup crew, and the complexes it forms with amyloid are cleared across the blood-brain barrier at a substantially lower rate than those formed by e2 or e3. To make things worse, e4 can actually cause breakdown of the blood-brain barrier itself, reducing blood flow to the brain. Over decades, the result is faster amyloid buildup, more of the tangled protein clumps associated with Alzheimer’s, and earlier symptom onset.
The e2 variant works in the opposite direction. Carriers of e2 have about 50% lower risk of Alzheimer’s compared to people with two copies of e3. Brain imaging shows that amyloid accumulates more slowly in e2 carriers as they age, and they reach the threshold for detectable amyloid buildup at a later age. Even among people who do develop significant amyloid deposits, e2 carriers are more likely to remain cognitively intact. Alzheimer’s patients who carry e2 also show slower cognitive decline over time. This protection extends through multiple pathways: e2 reduces amyloid plaque formation, limits the spread of tau tangles (another hallmark of the disease), and appears to support brain resilience through mechanisms that don’t involve amyloid at all.
Effects on Heart Health
Alzheimer’s gets the most attention, but the APOE gene also influences cardiovascular risk. The e4 allele is linked to higher LDL cholesterol levels, even in young people. This connection to elevated LDL contributes to faster development of arterial plaque. Studies of people over 65 found that those with two copies of e4 were roughly twice as likely to have carotid artery plaque compared to people with the e3/e3 genotype. In elderly e4 carriers, variation in blood levels of the APOE protein itself was associated with a threefold difference in stroke risk.
That said, the cardiovascular picture is more complex than the Alzheimer’s link. Some studies of older adults haven’t found a significant increase in heart attack risk among e4 carriers, and the relationship between LDL levels and cardiovascular events may weaken with age. The e4 allele appears to be a clearer risk factor for atherosclerosis (plaque buildup in arteries) and stroke than for heart attacks specifically.
APOE e2 and Living Longer
The e2 variant shows up disproportionately often in centenarians. People who live past 100, along with their children, carry the e2 allele at higher rates than the general population. The National Institute on Aging notes that e2 appears to promote longevity, though the exact biological reasons aren’t fully mapped. Given its protective effects against both Alzheimer’s and amyloid buildup, and its superior performance in clearing brain waste, the connection to longer life likely reflects cumulative protection against neurodegeneration and possibly cardiovascular disease over a lifetime.
How Lifestyle Interacts With Your Genotype
One of the most practical findings about the APOE gene is that lifestyle choices don’t just add to genetic risk; they multiply it. Physical inactivity, smoking, and alcohol consumption increase dementia risk more sharply in e4 carriers than in non-carriers. Diet matters too: consuming low levels of healthy polyunsaturated fats or high levels of saturated fat raises dementia risk more dramatically for people with the e4 allele. A population-based study found that adopting healthy lifestyle habits (staying physically active, not smoking, drinking moderately or not at all, eating well) could reduce an e4 carrier’s dementia risk to a level close to that of someone without the e4 allele. In other words, the e4 variant amplifies the consequences of unhealthy choices, but it also amplifies the benefit of healthy ones.
Genetic Testing for APOE
APOE testing is available through both clinical labs and direct-to-consumer genetic testing companies. However, it’s not yet part of routine medical practice. Current clinical guidelines don’t recommend screening asymptomatic people for APOE status as a standard procedure. The main clinical use right now is in research settings and in evaluating candidates for newer Alzheimer’s treatments that target amyloid. Carriers of e4 face a higher risk of side effects from these drugs, specifically a type of brain swelling or microbleeding that shows up on imaging, so knowing APOE status helps guide treatment decisions for people who already have symptoms.
For healthy people considering testing, the result is probabilistic, not deterministic. Plenty of e4 carriers never develop Alzheimer’s, and plenty of people with the “neutral” e3/e3 genotype do. The most actionable takeaway from an e4 result is the same advice that benefits everyone: regular exercise, a diet rich in unsaturated fats, limited alcohol, and no smoking. Those behaviors simply carry extra weight for e4 carriers.